News

The number of autoantibodies and congenital heart block pregnancies expanded to approximately 30 different autoantibodies to different targets near term.

The results show improvements in RAPID3, pain, fatigue, and morning stiffness at weeks 8 and 12 among patients treated with upadacitinib.

New research suggests that certain interleukin-17 blockage therapies may not alleviate sleeping issues in patients with psoriasis.

Intravitreal aflibercept, bevacizumab and ranibizumab were each associated with comparable significant decreases in RGCL thickness in nAMD.

Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.

A discussion with Dr. Lal regarding a recent 12-week trial evaluating the use of topical berdazimer gel for molluscum contagiosum.

Patients with ankylosing spondylitis generally had more favorable outcomes compared to those with psoriasis or psoriatic arthritis.

The analysis additionally suggested the potential benefits of finerenone in the prevention of required ocular interventions.

In data presented during ACR, investigators find peresolimab could be an effective treatment for adult patients with rheumatoid arthritis.

David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.

A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.

Because unhealthy sleep is associated with multiple conditions and higher risk of mortality, investigators call for further research on the potential to optimize overall sleep health in the US.

New research suggests the use of simvastatin treatment may be helpful for patients with nonsegmental vitiligo and dyslipidemia.

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

Gary Garcia-Molina, PhD, explains precisely how Sleep Number smart bed technology works after conducting multiple sleep studies.

Aruna Pradhan, MD, MPH, joins The Heart Team at AHA 2022 to discuss the design, results, and her interpretation of the PROMINENT trial for practicing clinicians as well as how she interprets use of triglyceride-lowering agents in the wake of PROMINENT and RESPECT-EPA results.

The efficacy of H pylori treatments has waned in recent years, largely because of clarithromycin resistance.

A new population-based study demonstrates an association between patients having systemic sclerosis and vitiligo, suggesting both conditions may need to be monitored for comorbidities.

At AHA 2022, Dr. Ray discusses the findings from the phase II open-label extension trial and highlights other important trial data for lipidologists.

A pair of studies leveraging NIS data detail the risk of cardiovascular complications during delivery admissions among pregnant persons with a history of systemic lupus erythematosus or use of assisted reproductive technologies relative to their counterparts who did not.

New research indicated that topical 5 FU for patients with vitiligo may be an option that is both a promising and cost-effective treatment for the skin condition.

The approval of risankizumab represents the first ever IL-23 approved by the FDA for IBD.

Nonprofit organizations combined efforts to plan a meeting to inform and educate the FDA and key stakeholders about the experience of caregivers and patients with Phelan-McDermid syndrome (PMS).

A recent discussion with Dr. Brown on the use of tapinarof, approved for adult plaque psoriasis, in patients with atopic dermatitis.

A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.

Ridker joins to discuss some of his recent work, provide a deep dive into use of inflammatory biomarkers for identifying patients with residual inflammatory risk, provide perspective on use of MACE compared with all-cause mortality in cardiovascular clinical trials, and discuss the optimized uptake of SGLT2 inhibitors in care.

The most frequent psychiatric disorder that appeared in patients with ADHD was substance use disorder, followed by mood disorders, anxiety disorders, and personality disorders.

A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.

On Chen, MD, director of the Cardiac Intensive Care Unit and the Advanced Lipid Management Program at Stony Brook University, takes hosts Jorge Plutzky, MD, and Michael Farkouh, MD, on a deep dive into clinical processes at his institution and his perspective on some of the latest advances in lipid management.

At the International Pediatric Sleep Association (IPSA) Congress 2022, investigators from Sleep Number presented 2 investigations that utilized its smart bed technology to analyze pediatric sleep behaviors.